Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Takeda, Arbor aim to stop Turkish copies of high blood pressure drug

22 March 2022 Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi.

Big Pharma

EUIPO sides with Takeda in trademark appeal

28 November 2018 Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office that an applied-for trademark would be confused with its own earlier-registered mark

Asia

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

29 August 2017 AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

More on this story

Editor's picks

Editor's picks

More features